Treatment regimen for study Total XIIIB
Window treatment | HDMTX + 6MP, LDMTX + 6MP, or 6MP (d 1-3) |
| Remission induction | |
| Days 1-28 | Vincristine × 4, daunorubicin × 2l-asparaginase × 6-9 |
| Etoposide + Ara-C (d 22, d 25) | |
| Prednisone (40 mg/m2/d, d 1 to d 28) | |
| Day 29 | Etoposide* (300 mg/m2) + Ara-C (300 mg/m2) |
| Consolidation | HDMTX + 6MP (2 wk) |
| Continuation (SR/HR group) | |
| Weeks 1-15 | Weekly rotating drug pairs |
| Weeks 16-19 | Reinduction; similar protocol as d 1 to d 28 |
| Weeks 20-21 | HDMTX + 6MP (2 wk) |
| Weeks 22-50 | Weekly rotating drug pairs |
| Week 51 | Dexamethasone + vincristine |
| Week 52 | Etoposide + cyclophosphamide |
| Week 53 | 6MP + MTX |
| Week 54 | Etoposide* (300 mg/m2) + Ara-C (300 mg/m2) |
Window treatment | HDMTX + 6MP, LDMTX + 6MP, or 6MP (d 1-3) |
| Remission induction | |
| Days 1-28 | Vincristine × 4, daunorubicin × 2l-asparaginase × 6-9 |
| Etoposide + Ara-C (d 22, d 25) | |
| Prednisone (40 mg/m2/d, d 1 to d 28) | |
| Day 29 | Etoposide* (300 mg/m2) + Ara-C (300 mg/m2) |
| Consolidation | HDMTX + 6MP (2 wk) |
| Continuation (SR/HR group) | |
| Weeks 1-15 | Weekly rotating drug pairs |
| Weeks 16-19 | Reinduction; similar protocol as d 1 to d 28 |
| Weeks 20-21 | HDMTX + 6MP (2 wk) |
| Weeks 22-50 | Weekly rotating drug pairs |
| Week 51 | Dexamethasone + vincristine |
| Week 52 | Etoposide + cyclophosphamide |
| Week 53 | 6MP + MTX |
| Week 54 | Etoposide* (300 mg/m2) + Ara-C (300 mg/m2) |
HDMTX indicates high-dose methotrexate; LDMTX, low-dose methotrexate; 6MP, 6-mercaptopurine; SR, standard risk; HR, high risk; Ara-C, cytosine arabinoside.
Time point for etoposide pharmacokinetics.